Dietary fat, abdominal obesity and smoking modulate the relationship between plasma complement component 3 concentrations and metabolic syndrome risk

Atherosclerosis

Volumn 220, Issue 2, 2012, Pages 513-519

  Phillips, Catherine M ^a,b   Kesse Guyot, Emmanuelle ^c   Ahluwalia, Namanjeet ^c   McManus, Ross ^d   Hercberg, Serge ^c,e   Lairon, Denis ^f   Planells, Richard ^f   Roche, Helen M ^a  

^a UNIVERSITY COLLEGE DUBLIN   (Ireland)

^b UNIVERSITY COLLEGE CORK   (Ireland)

^c UNIVERSITÉ PARIS 13   (France)

^d TRINITY COLLEGE DUBLIN   (Ireland)

^e AVICENNE HOSPITAL   (France)

^f INSERM   (France)

Author keywords

Cardiovascular risk factors; Diet; Inflammation; LIPGENE; Metabolic syndrome; Obesity; Smoking

Indexed keywords

COMPLEMENT COMPONENT C3; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; MONOUNSATURATED FATTY ACID; SATURATED FATTY ACID;

ABDOMINAL OBESITY; ADULT; ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; FAT INTAKE; FEMALE; FOLLOW UP; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIFESTYLE; LIPID COMPOSITION; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; OBESITY; PHENOTYPE; PHYSICAL ACTIVITY; PRIORITY JOURNAL; RISK ASSESSMENT; SMOKING HABIT;

ADULT; ANALYSIS OF VARIANCE; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CHOLESTEROL, HDL; COMPLEMENT C3; DIETARY FATS; FEMALE; FRANCE; HUMANS; INSULIN; INSULIN RESISTANCE; LINEAR MODELS; LOGISTIC MODELS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; OBESITY, ABDOMINAL; ODDS RATIO; PHENOTYPE; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SMOKING; UP-REGULATION;

EID: 84855978209     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2011.11.007     Document Type: Article

References (45)

1. Moller D.E., Kaufman K.D. Metabolic syndrome: a clinical and molecular perspective. Annual Review of Medicine 2005, 56:45-62.
2. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143-421.
3. Maury E., Brichard S.M. Adipokine dysregulation, adipose tissue inflammation and metabolic syndrome. Molecular and Cellular Endocrinology 2010, 314:1-16.
4. Pickup J.C. Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes. Diabetes Care 2004, 27:813-823.
5. Engstrom G., Hedblad B., Eriksson K.F., Janzon L., Lindgarde F. Complement C3 is a risk factor for the development of diabetes: a population-based cohort study. Diabetes 2005, 54:570-575.
6. Halkes C.J., van Dijk H., de Jaegere P.P., et al. Postprandial increase of complement component 3 in normolipidemic patients with coronary artery disease: effects of expanded-dose simvastatin. Arteriosclerosis, Thrombosis, and Vascular Biology 2001, 21:1526-1530.
7. Muscari A., Massarelli G., Bastagli L., et al. Relationship of serum C3 to fasting insulin, risk factors and previous ischaemic events in middle-aged men. European Heart Journal 2000, 21:1081-1090.
8. van Oostrom A.J., Alipour A., Plokker T.W., Sniderman A.D., Cabezas M.C. The metabolic syndrome in relation to complement component 3 and postprandial lipemia in patients from an outpatient lipid clinic and healthy volunteers. Atherosclerosis 2007, 190:167-173.
9. Gabrielsson B.G., Johansson J.M., Lonn M., et al. High expression of complement components in omental adipose tissue in obese men. Obesity Research 2003, 11:699-708.
10. Hernandez-Mijares A., Jarabo-Bueno M.M., Lopez-Ruiz A., et al. Levels of C3 in patients with severe, morbid and extreme obesity: its relationship to insulin resistance and different cardiovascular risk factors. International Journal of Obesity (2005) 2007, 31:927-932.
11. Yang Y., Lu H.L., Zhang J., et al. Relationships among acylation stimulating protein, adiponectin and complement C3 in lean vs obese type 2 diabetes. International Journal of Obesity (2005) 2006, 30:439-446.
12. Masharani U.B., Maddux B.A., Li X., et al. Insulin resistance in non-obese subjects is associated with activation of the JNK pathway and impaired insulin signaling in skeletal muscle. PloS ONE 2011, 6:e19878.
13. Phillips C.M., Goumidi L., Bertrais S., et al. Complement component 3 polymorphisms interact with polyunsaturated fatty acids to modulate risk of metabolic syndrome. The American Journal of Clinical Nutrition 2009, 90:1665-1673.
14. Phillips C., Lopez-Miranda J., Perez-Jimenez F., McManus R., Roche H.M. Genetic and nutrient determinants of the metabolic syndrome. Current Opinion in Cardiology 2006, 21:185-193.
15. Szabo de Edelenyi F., Goumidi L., Bertrais S., et al. Prediction of the metabolic syndrome status based on dietary and genetic parameters, using Random Forest. Genes & Nutrition 2008, 3:173-176.
16. Vessby B. Dietary fat, fatty acid composition in plasma and the metabolic syndrome. Current Opinion in Lipidology 2003, 14:15-19.
17. Lopez-Miranda J., Williams C., Lairon D. Dietary, physiological, genetic and pathological influences on postprandial lipid metabolism. The British Journal of Nutrition 2007, 98:458-473.
18. Scantlebury T., Maslowska M., Cianflone K. Chylomicron-specific enhancement of acylation stimulating protein and precursor protein C3 production in differentiated human adipocytes. The Journal of Biological Chemistry 1998, 273:20903-20909.
19. Verseyden C., Meijssen S., van Dijk H., Jansen H., Castro Cabezas M. Effects of atorvastatin on fasting and postprandial complement component 3 response in familial combined hyperlipidemia. Journal of Lipid Research 2003, 44:2100-2108.
20. Engstrom G., Hedblad B., Janzon L., Lindgarde F. Weight gain in relation to plasma levels of complement factor 3: results from a population-based cohort study. Diabetologia 2005, 48:2525-2531.
21. Onat A., Hergenc G., Can G., Kaya Z., Yuksel H. Serum complement C3: a determinant of cardiometabolic risk, additive to the metabolic syndrome, in middle-aged population. Metabolism: Clinical and Experimental 2010, 59:628-634.
22. Puchau B., Zulet M.A., Gonzalez de Echavarri A., Navarro-Blasco I., Martinez J.A. Selenium intake reduces serum C3, an early marker of metabolic syndrome manifestations, in healthy young adults. European Journal of Clinical Nutrition 2009, 63:858-864.
23. van Greevenbroek M.M., Jacobs M., van der Kallen C.J., et al. Human plasma complement C3 is independently associated with coronary heart disease, but only in heavy smokers (the CODAM study). International Journal of Cardiology 2010, in press.
24. Hercberg S., Galan P., Preziosi P., et al. The SU.VI.MAX Study: a randomized, placebo-controlled trial of the health effects of antioxidant vitamins and minerals. Archives of Internal Medicine 2004, 164:2335-2342.
25. Phillips C.M., Goumidi L., Bertrais S., et al. Dietary saturated fat modulates the association between STAT3 polymorphisms and abdominal obesity in adults. The Journal of Nutrition 2009, 139:2011-2017.
26. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.
27. Matthews D.R., Hosker J.P., Rudenski A.S., et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28:412-419.
28. Perseghin G., Caumo A., Caloni M., Testolin G., Luzi L. Incorporation of the fasting plasma FFA concentration into QUICKI improves its association with insulin sensitivity in nonobese individuals. The Journal of Clinical Endocrinology and Metabolism 2001, 86:4776-4781.
29. Liang K.Y., Zeger S.L. Regression analysis for correlated data. Annual Review of Public Health 1993, 14:43-68.
30. Gregor M.F., Hotamisligil G.S. Inflammatory mechanisms in obesity. Annual Review of Immunology 2011, 29:415-445.
31. Kennedy A., Martinez K., Chuang C.C., LaPoint K., McIntosh M. Saturated fatty acid-mediated inflammation and insulin resistance in adipose tissue: mechanisms of action and implications. The Journal of Nutrition 2009, 139:1-4.
32. Tierney A.C., McMonagle J., Shaw D.I., et al. Effects of dietary fat modification on insulin sensitivity and on other risk factors of the metabolic syndrome-LIPGENE: a European randomized dietary intervention study. International Journal of Obesity (2005) 2011, 35(Jun (6)):800-809.
33. Kien C.L., Bunn J.Y., Ugrasbul F. Increasing dietary palmitic acid decreases fat oxidation and daily energy expenditure. The American Journal of Clinical Nutrition 2005, 82:320-326.
34. Mamane Y., Chung Chan C., Lavallee G., et al. The C3a anaphylatoxin receptor is a key mediator of insulin resistance and functions by modulating adipose tissue macrophage infiltration and activation. Diabetes 2009, 58(Sep (9)):2006-2017.
35. Recinos A., Carr B.K., Bartos D.B., et al. Liver gene expression associated with diet and lesion development in atherosclerosis-prone mice: induction of components of alternative complement pathway. Physiological Genomics 2004, 19:131-142.
36. van Dijk S.J., Feskens E.J., Bos M.B., et al. A saturated fatty acid-rich diet induces an obesity-linked proinflammatory gene expression profile in adipose tissue of subjects at risk of metabolic syndrome. The American Journal of Clinical Nutrition 2009, 90:1656-1664.
37. Hermsdorff H.H., Zulet M.A., Abete I., Martinez J.A. A legume-based hypocaloric diet reduces proinflammatory status and improves metabolic features in overweight/obese subjects. European Journal of Nutrition 2011, 50:61-69.
38. Shi H., Kokoeva M.V., Inouye K., et al. TLR4 links innate immunity and fatty acid-induced insulin resistance. The Journal of Clinical Investigation 2006, 116:3015-3025.
39. Holland W.L., Bikman B.T., Wang L.P., et al. Lipid-induced insulin resistance mediated by the proinflammatory receptor TLR4 requires saturated fatty acid-induced ceramide biosynthesis in mice. The Journal of Clinical Investigation 2011, 121:1858-1870.
40. Nguyen M.T., Favelyukis S., Nguyen A.K., et al. A subpopulation of macrophages infiltrates hypertrophic adipose tissue and is activated by free fatty acids via Toll-like receptors 2 and 4 and JNK-dependent pathways. The Journal of Biological Chemistry 2007, 282:35279-35292.
41. Davis J.E., Gabler N.K., Walker-Daniels J., Spurlock M.E. Tlr-4 deficiency selectively protects against obesity induced by diets high in saturated fat. Obesity (Silver Spring, Md) 2008, 16:1248-1255.
42. Hajishengallis G., Lambris J.D. Crosstalk pathways between Toll-like receptors and the complement system. Trends in Immunology 2010, 31:154-163.
43. Zhang X., Kimura Y., Fang C., et al. Regulation of Toll-like receptor-mediated inflammatory response by complement in vivo. Blood 2007, 110:228-236.
44. Szeplaki G., Prohaszka Z., Duba J., et al. Association of high serum concentration of the third component of complement (C3) with pre-existing severe coronary artery disease and new vascular events in women. Atherosclerosis 2004, 177:383-389.
45. Maslowska M., Vu H., Phelis S., et al. Plasma acylation stimulating protein, adipsin and lipids in non-obese and obese populations. European Journal of Clinical Investigation 1999, 29:679-686.